Updates on the systemic treatment of advanced non-melanoma skin cancer

Research output: Contribution to journalReview article

Abstract

Non-melanoma skin cancers (NMSCs), which represent a diverse group of cutaneous malignancies, are the most common forms of human neoplasia. The incidence of these diseases is increasing due to a number of factors, including that of increasing human lifespans. The majority of NMSCs are basal cell carcinomas (BCC) and cutaneous squamous cell carcinomas (cSCC), with the remainder being various rare skin cancers, including extramammary Paget's disease (EMPD), Merkel cell carcinoma (MCC), and several skin adnexal carcinomas. Of these, MCC usually shows aggressive behavior with a high mortality rate. On the other hand, BCC, cSCC, EMPD, and skin adnexal tumors usually show an indolent clinical course and metastasize only rarely. Nevertheless, the metastatic forms of these tumors commonly lead to poor patient outcome. A definitive management strategy for the treatment of advanced NMSC has not been established, mainly due to their rarity and lack of reliable information based on well-controlled randomized trials. Chemotherapeutic regimens for treatment of these diseases have been mainly based on the observations of isolated, small case series or clinical trials with a limited numbers of patients. However, accumulating evidence regarding their pathobiological backgrounds as well as recent advances in molecular biotechnology have facilitated the development of novel drugs for treatment of these diseases. Over the past decade, the U.S. Food and Drug Administration has approved several molecular targeting therapies, including Hedgehog inhibitors for BCC, monoclonal antibodies targeting anti-programmed death ligand-1 and anti- programmed cell death 1 (PD-1) for MCC, and anti-PD-1 for cSCC. Here, we review their clinical utility and discuss updated systemic treatment strategies for advanced NMSC.

Original languageEnglish
Article number160
JournalFrontiers in Medicine
Volume6
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Skin Neoplasms
Merkel Cell Carcinoma
Skin
Basal Cell Carcinoma
Extramammary Paget's Disease
Squamous Cell Carcinoma
CD274 Antigen
Neoplasms
Therapeutics
United States Food and Drug Administration
Biotechnology
Cell Death
Randomized Controlled Trials
Monoclonal Antibodies
Clinical Trials
Carcinoma
Mortality
Incidence
Pharmaceutical Preparations

Keywords

  • Adnexal carcinoma
  • Basal cell carcinoma
  • Extramammary Paget's disease
  • Merkel cell carcinoma
  • Squamous cell carcinoma

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Updates on the systemic treatment of advanced non-melanoma skin cancer. / Tanese, Keiji; Nakamura, Yoshio; Hirai, Ikuko; Funakoshi, Takeru.

In: Frontiers in Medicine, Vol. 6, 160, 01.01.2019.

Research output: Contribution to journalReview article

@article{c81a969212094e7dae06b48d4acbb519,
title = "Updates on the systemic treatment of advanced non-melanoma skin cancer",
abstract = "Non-melanoma skin cancers (NMSCs), which represent a diverse group of cutaneous malignancies, are the most common forms of human neoplasia. The incidence of these diseases is increasing due to a number of factors, including that of increasing human lifespans. The majority of NMSCs are basal cell carcinomas (BCC) and cutaneous squamous cell carcinomas (cSCC), with the remainder being various rare skin cancers, including extramammary Paget's disease (EMPD), Merkel cell carcinoma (MCC), and several skin adnexal carcinomas. Of these, MCC usually shows aggressive behavior with a high mortality rate. On the other hand, BCC, cSCC, EMPD, and skin adnexal tumors usually show an indolent clinical course and metastasize only rarely. Nevertheless, the metastatic forms of these tumors commonly lead to poor patient outcome. A definitive management strategy for the treatment of advanced NMSC has not been established, mainly due to their rarity and lack of reliable information based on well-controlled randomized trials. Chemotherapeutic regimens for treatment of these diseases have been mainly based on the observations of isolated, small case series or clinical trials with a limited numbers of patients. However, accumulating evidence regarding their pathobiological backgrounds as well as recent advances in molecular biotechnology have facilitated the development of novel drugs for treatment of these diseases. Over the past decade, the U.S. Food and Drug Administration has approved several molecular targeting therapies, including Hedgehog inhibitors for BCC, monoclonal antibodies targeting anti-programmed death ligand-1 and anti- programmed cell death 1 (PD-1) for MCC, and anti-PD-1 for cSCC. Here, we review their clinical utility and discuss updated systemic treatment strategies for advanced NMSC.",
keywords = "Adnexal carcinoma, Basal cell carcinoma, Extramammary Paget's disease, Merkel cell carcinoma, Squamous cell carcinoma",
author = "Keiji Tanese and Yoshio Nakamura and Ikuko Hirai and Takeru Funakoshi",
year = "2019",
month = "1",
day = "1",
doi = "10.3389/fmed.2019.00160",
language = "English",
volume = "6",
journal = "Frontiers in Medicine",
issn = "2296-858X",
publisher = "Frontiers Media S. A.",

}

TY - JOUR

T1 - Updates on the systemic treatment of advanced non-melanoma skin cancer

AU - Tanese, Keiji

AU - Nakamura, Yoshio

AU - Hirai, Ikuko

AU - Funakoshi, Takeru

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Non-melanoma skin cancers (NMSCs), which represent a diverse group of cutaneous malignancies, are the most common forms of human neoplasia. The incidence of these diseases is increasing due to a number of factors, including that of increasing human lifespans. The majority of NMSCs are basal cell carcinomas (BCC) and cutaneous squamous cell carcinomas (cSCC), with the remainder being various rare skin cancers, including extramammary Paget's disease (EMPD), Merkel cell carcinoma (MCC), and several skin adnexal carcinomas. Of these, MCC usually shows aggressive behavior with a high mortality rate. On the other hand, BCC, cSCC, EMPD, and skin adnexal tumors usually show an indolent clinical course and metastasize only rarely. Nevertheless, the metastatic forms of these tumors commonly lead to poor patient outcome. A definitive management strategy for the treatment of advanced NMSC has not been established, mainly due to their rarity and lack of reliable information based on well-controlled randomized trials. Chemotherapeutic regimens for treatment of these diseases have been mainly based on the observations of isolated, small case series or clinical trials with a limited numbers of patients. However, accumulating evidence regarding their pathobiological backgrounds as well as recent advances in molecular biotechnology have facilitated the development of novel drugs for treatment of these diseases. Over the past decade, the U.S. Food and Drug Administration has approved several molecular targeting therapies, including Hedgehog inhibitors for BCC, monoclonal antibodies targeting anti-programmed death ligand-1 and anti- programmed cell death 1 (PD-1) for MCC, and anti-PD-1 for cSCC. Here, we review their clinical utility and discuss updated systemic treatment strategies for advanced NMSC.

AB - Non-melanoma skin cancers (NMSCs), which represent a diverse group of cutaneous malignancies, are the most common forms of human neoplasia. The incidence of these diseases is increasing due to a number of factors, including that of increasing human lifespans. The majority of NMSCs are basal cell carcinomas (BCC) and cutaneous squamous cell carcinomas (cSCC), with the remainder being various rare skin cancers, including extramammary Paget's disease (EMPD), Merkel cell carcinoma (MCC), and several skin adnexal carcinomas. Of these, MCC usually shows aggressive behavior with a high mortality rate. On the other hand, BCC, cSCC, EMPD, and skin adnexal tumors usually show an indolent clinical course and metastasize only rarely. Nevertheless, the metastatic forms of these tumors commonly lead to poor patient outcome. A definitive management strategy for the treatment of advanced NMSC has not been established, mainly due to their rarity and lack of reliable information based on well-controlled randomized trials. Chemotherapeutic regimens for treatment of these diseases have been mainly based on the observations of isolated, small case series or clinical trials with a limited numbers of patients. However, accumulating evidence regarding their pathobiological backgrounds as well as recent advances in molecular biotechnology have facilitated the development of novel drugs for treatment of these diseases. Over the past decade, the U.S. Food and Drug Administration has approved several molecular targeting therapies, including Hedgehog inhibitors for BCC, monoclonal antibodies targeting anti-programmed death ligand-1 and anti- programmed cell death 1 (PD-1) for MCC, and anti-PD-1 for cSCC. Here, we review their clinical utility and discuss updated systemic treatment strategies for advanced NMSC.

KW - Adnexal carcinoma

KW - Basal cell carcinoma

KW - Extramammary Paget's disease

KW - Merkel cell carcinoma

KW - Squamous cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85068899650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068899650&partnerID=8YFLogxK

U2 - 10.3389/fmed.2019.00160

DO - 10.3389/fmed.2019.00160

M3 - Review article

AN - SCOPUS:85068899650

VL - 6

JO - Frontiers in Medicine

JF - Frontiers in Medicine

SN - 2296-858X

M1 - 160

ER -